Drugging the PI3 kinome: From chemical tools to drugs in the clinic

Cancer Research

Volumn 70, Issue 6, 2010, Pages 2146-2157

  Workman, Paul ^a,b   Clarke, Paul A ^a,b   Raynaud, Florence I ^a,b   Van Montfort, Rob L M ^b  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 (1H INDAZOL 4 YL) 6 (4 METHANESULFONYL 1 PIPERAZINYLMETHYL) 4 MORPHOLINOTHIENO[3,2 D]PYRIMIDINE; 2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 2 MORPHOLINO 8 PHENYLCHROMONE; ANTINEOPLASTIC AGENT; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PI 540; PI 620; THIENOPYRIDINE DERIVATIVE; UNCLASSIFIED DRUG; WORTMANNIN;

ANTINEOPLASTIC ACTIVITY; CANCER MODEL; CANCER PATIENT; DRUG DESIGN; DRUG EFFECT; GLIOMA; HUMAN; MEDICAL LITERATURE; NONHUMAN; PRIORITY JOURNAL; REVIEW; STRUCTURE ANALYSIS; SYSTEMATIC REVIEW;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; DRUG DELIVERY SYSTEMS; FURANS; HUMANS; INDAZOLES; MODELS, MOLECULAR; NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRIMIDINES; SULFONAMIDES;

EID: 77950243447     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-4355     Document Type: Review

References (69)

1. Vanhaesebroeck B, Leevers SJ, Ahmadi K, et al. Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem 2001;70:535-602.
2. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002;296:1655-1657
3. Abraham RT. PI 3-kinase related kinases: 'big' players in stress-induced signaling pathways. DNA Repair (Amst) 2004;3:883-887
4. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008;27:5497-5510
5. Liu P, Cheng H, Roberts TM, Zhao JJ. Disc Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009;8:627-644
6. Ligresti G, Militello L, Steelman LS, et al. PIK3CA mutations in human solid tumors. Cell Cycle 2009;8:1352-1358
7. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the Pik3CA in human cancers. Science 2004;304:554.
8. Engelman JA, Chen L, Tan X, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008;14:1351-1356
9. Vogt PK, Gymnopoulos M, Hart PI, Jr. 3-kinase and cancer: changing accents. Curr Opin Genet Dev 2009;19:12-17
10. Collins I, Workman P. New approaches to molecular cancer therapeutics. Nat Chem Biol 2006;2:689-700.
11. Workman P.Drugging the cancer genome: newchallenges of infrequent and combinatorial targets. Curr Opin Investig Drugs 2007;8:445-446
12. Workman P, Clarke PA, Gulliard S, Raynaud FI. Drugging the PI3 kinome. Nat Biotechnol 2006;24:1033.
13. Knight ZA, Shokat KM. Chemically targeting the PI3K family. Biochem Soc Trans 2007;35:245-249
14. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000;351:95-105.
15. Bain J, McLauchlan H, Elliott M, Cohen P. The specificities of protein kinase inhibitors. Biochem J 2003;371:199-204.
16. Bain J, Plater L, Elliott M, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J 2007;408:297-315.
17. Baggiolini M, Dewald B, Schnyder J, Ruch W, Cooper PH, Payne TG. Inhibition of the phagocytosis-induced respiratory burst by the fungal metabolite wortmannin and some analogues. Exp Cell Res 1987;169:408-418
18. Arcaro A, Wymann MP. Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil response. Biochem J 1993;296:297-301.
19. Wymann MP, Bulgarelli-Leva G, Zvelebil MJ, et al. Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction. Mol Cell Biol 1996;16:1722-1733
20. Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 1994;269:5241-5248
21. Cohen P. Protein kinase - the major targets of the twenty-first century. Nat Rev Drug Discov 2002;1:309-315
22. Garcia-Echeverria C, Sellers WR. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 2008;27:5511-5526
23. Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, Workman P. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls and promises. Curr Opin Pharmacol 2008;8:393-412.
24. Drees BE, Mills GB, Rommel C, Prestwich GD. Therapeutic potential of phosphoinositide 3-kinase inhibitors. Exp Opin Ther 2004;14:1354-3776.
25. Crabbe T, Welham MJ, Ward SG. The PI3K inhibitor arsenal: choose your weapon!. Trends Biochem Sci 2007;32:450-456
26. Walker EH, Pacold ME, Perisic O, et al. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell 2000;6:909-919
27. HayakawaM, KaizawaH,MoritomoH, et al.Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110α inhibitors. Bioorg Med Chem 2006;14:6847-6858
28. Hayakawa M, Kaizawa H, Kawaguchi K, et al. Synthesis and biological evaluation of imidazo[1,2-a]pyridine derivatives as novel PI3 kinase p110α inhibitors. Bioorg Med Chem 2007;15:403-412
29. Hayakawa M, Kaizawa H, Moritomo H, et al. Synthesis and biological evaluation of pyrido[3′,2′:4,5]furo[3,2-d]pyrimidine derivatives as novel PI3 kinase p110α inhibitors. Bioorg Med Chem Lett 2007;17:2438-2442
30. Hayakawa M, Kawaguchi K, Kaizawa H, et al. Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110α inhibitors. Bioorg Med Chem 2007;15:5837-5844
31. Workman P. Drugging the cancer kinome: progress and challenges in developing personalized molecular cancer therapeutics. Cold Spring Harb Quant Biol 2005;70:499-515.
32. Workman P, Raynaud FI, Clarke PA, et al. Pharmacological properties and in vitro and in vivo antitumor activity of the potent and selective PI3 kinase inhibitor PI103. Eur J Cancer 2004;40:414A.
33. Raynaud FI, Eccles S, Clarke PA, et al. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res 2007;67:5840-5850
34. Guillard S, Clarke PA, Te Poele R, et al. Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma. Cell Cycle 2009;8:443-453
35. Knight ZA, Gonzalez B, Feldman ME, et al. A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling. Cell 2006;125:733-747
36. Foukas LC, Claret M, Pearce W, et al. Critical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 2006;441:366-370
37. FanQW, Knight ZA, Goldenberg DD, et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 2006;9:341-349
38. 1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl) -4-morpholin- 4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I P13 kinase for the treatment of cancer. J Med Chem 2008;51:5522-5532
39. Raynaud FI, Eccles SA, Patel S, et al. Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol Cancer Ther 2009;8:1725-1738
40. Gowan SM, Hardcastle A, Hallsworth AE, et al. Application of meso scale technology for the measurement of phosphoproteins in human tumor xenografts. Assay Drug Dev Technol 2007;5:391-401.
41. Friedman L. GDC-0941, a potent selective orally bioavailable inhibitor of class I PI3K. Proc American Assoc Cancer Res 2008:LB-110.
42. Workman P. Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics. Mol Cancer Ther 2003;2:131-138
43. Sarker D, Workman P. Pharmacodynamic biomarkers for molecular cancer therapeutics. Adv Cancer Res 2007;96:213-268
44. Walker EH, Perisic O, Ried C, Stephens l, Williams RL. Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature 1999;402:313-320
45. Huang C-H, Mandelker D, Schmidt-Kittler O, et al. The structure of a human p110a/p85a complex elucidates the effects of oncogenic PI3Ka mutations. Science 2007;318:1744-1748
46. Frazzetto M, Suphioglu C, Zhu J, et al. Dissecting isoform selectivity of PI3K inhibitors: the role of non-conserved residues in the catalytic pocket. Biochem J 2008;414:383-390
47. Berndt A, Miller S, Williams O, et al. The p110δ crystal structure uncovers mechanisms for selectivity and potency of novel PI3K inhibitors. Nat Chem Biol 2010;6:117-124
48. Zunder ER, Knight ZA, Houseman BT, Apsel B, Shokat KM. Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110α. Cancer Cell 2008;14:180-192
49. Editorial. Perfecting probes. Nat Chem Biol 2009;5:435.
50. Austin CP, Brady LS, Insel TR, Collins FS. NIH Molecular Libraries Initiative. Science 2004;306:1138-1139
51. Oprea TI, Bologa CG, Boyer S, et al. A crowdsourcing evaluation of the NIH chemical probes. Nat Chem Biol 2009;5:441-447
52. van Montfort RL, Workman P. Structure-based design of molecular cancer therapeutics. Trends Biotechnol 2009;27:315-328
53. Liu TJ, Koul D, LaFortune T, et al. NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol Cancer Ther 2009;8:2204-2210
54. Ihle NT, Powis G. Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy. Mol Cancer Ther 2009;8:1-9.
55. Wee S, Wiederschain D, Maira SM, et al. PTEN-deficient cancers depend on PIK3CB. Proc Natl Acad Sci U S A 2008;105:13057-13062
56. Jia S, Liu Z, Zhang S, et al. Essential roles of PI(3)K-p110β in cell growth, metabolism and tumorigenesis. Nature 2008;454:776-779
57. Vasudevan KM, Barbie DA, Davies MA, et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 2009;16:21-32.
58. Graupera M, Guillermet-Guibert J, Foukas LC, et al. Angiogenesis selectively requires the p110α isoform of PI3K to control endothelial cell migration. Nature 2008;453:662-666
59. Vilar E, Mukherjee B, Kuick R, et al. Gene expression patterns in mismatch repair-deficient colorectal cancers highlight the potential therapeutic role of inhibitors of the phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway. Clin Cancer Res 2009;15:2829-2839
60. Junttila TT, Akita RW, Parsons K, et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009;15:429-440
61. Yao E, Zhou W, Lee-Hoeflich ST, et al. Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab. Clin Cancer Res 2009;15:4147-4156
62. Hoeflich KP, Herter S, Tien J, et al. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. Cancer Res 2009;69:3042-3051
63. Hoeflich KP, O'Brien C, Boyd Z, et al. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res 2009;15:4649-4664
64. Sarker D, Kristeleit R, Mazina KE, et al. A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) of the oral panphosphoinositide- 3 kinase (PI3K) inhibitor GDC-0941. J Clin Oncol 2009;27:3538.
65. Wagner AJ, Von Hoff DH, LoRusso PM, et al. A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors. J Clin Oncol 2009;27:3501.
66. Workman P, van Montfort RL. Revealing the delta lady. Nat Chem Biol 2010; 6:82-83.
67. Potterton L, McNicholas S, Krissinel E, et al. Developments in the CCP4 molecular-graphics project. Acta Crystallogr D Crystallogr 2004;60:2288-2294
68. Collabrative Computational Project, Number 4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr 1994;D50:760-763
69. Sutherlin DP, Sampath D, Berry M, et al. Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancer. J Med Chem 2010 Jan 5. Epub ahead of print doi: 10.1021/jm901284w.